In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa lung infection
The ISME Journal · 08.01.2024 · 18 (1)
DOI: 10.1093/ismejo/wrae036 ↗Kurz gefasst
Fachartikel in der Zeitschrift The ISME Journal, online erschienen am 13.03.2024. Verfasst von Doaa Higazy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Costerton Biofilm Center, Department of Immunology and Microbiology, University of Copenhagen, 2200 N Copenhagen, Denmark. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Pseudomonas Infections. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Egyptian Ministry of Higher Education.
Abstract (Originalsprache)
The evolution of antimicrobial resistance (AMR) in biofilms has been repeatedly studied by experimental evolution in vitro, but rarely in vivo. The complex microenvironment at the infection site imposes selective pressures on the bacterial biofilms, potentially influencing the development of AMR. We report here the development of AMR in an in vivo mouse model of Pseudomonas aeruginosa biofilm lung infection. The P. aeruginosa embedded in seaweed alginate beads underwent four successive lung infection passages with or without ciprofloxacin (CIP) exposure. The development of CIP resistance was assessed at each passage by population analysis of the bacterial populations recovered from the lungs of CIP-treated and control mice, with subsequent whole-genome sequencing of selected isolates. As inflammation plays a crucial role in shaping the microenvironment at the infection site, its impact was explored through the measurement of cytokine levels in the lung homogenate. A rapid development of AMR was observed starting from the second passage in the CIP-treated mice. Genetic analysis revealed mutations in nfxB, efflux pumps (mexZ), and two-component systems (parS) contribution to CIP resistance. The control group isolates exhibited mutations in the dipA gene, likely associated with biofilm dispersion. In the initial two passages, the CIP-treated group exhibited an elevated inflammatory response compared to the control group. This increase may potentially contribute to the release of mutagenic reactive oxygen species and the development of AMR. In conclusion, this study illustrates the complex relationship between infection, antibiotic treatment, and immune response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Costerton Biofilm Center, Department of Immunology and Microbiology, University of Copenhagen, 2200 N Copenhagen, Denmark.
- Department of Microbiology, Faculty of Agriculture, Cairo University, 12613 Giza, Egypt.
- Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, 2100 Ø Copenhagen, Denmark.
- Division of Systems Pharmacology & Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, 2300 RA Leiden, The Netherlands.
- Department of Biotechnology and Biomedicine, Technical University of Denmark, 2800 Kgs. Lyngby, Denmark.
Förderung
- Egyptian Ministry of Higher Education
Zitieren
APA
Higazy, D., Pham, A. D., van Hasselt, C., Høiby, N., Jelsbak, L., Moser, C., & Ciofu, O. (2024). In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa lung infection. The ISME Journal, 18(1). https://doi.org/10.1093/ismejo/wrae036
Vancouver
Higazy D, Pham AD, van Hasselt C, Høiby N, Jelsbak L, Moser C, et al. In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa lung infection. The ISME Journal. 2024;18(1). doi:10.1093/ismejo/wrae036
BibTeX
@article{Higazy2024,
author = {Higazy, Doaa and Pham, Anh Duc and van Hasselt, Coen and Høiby, Niels and Jelsbak, Lars and Moser, Claus and Ciofu, Oana},
title = {In vivo evolution of antimicrobial resistance in a biofilm model of Pseudomonas aeruginosa lung infection},
journal = {The ISME Journal},
year = {2024},
volume = {18},
number = {1},
doi = {10.1093/ismejo/wrae036}
}
EUVIMED